| Dr Meghan E Cavazos, PHARMD | |
|
3095 N Montana Ave, Helena, MT 59601-0552 | |
| (406) 443-3331 | |
| Not Available |
| Full Name | Dr Meghan E Cavazos |
|---|---|
| Gender | Female |
| Speciality | Pharmacist |
| Location | 3095 N Montana Ave, Helena, Montana |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1114284866 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | PH60162002 (Washington) | Secondary |
| 183500000X | Pharmacist | 1607840 (Wisconsin) | Secondary |
| 183500000X | Pharmacist | 15067 (Montana) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Meghan E Cavazos, PHARMD 3095 N Montana Ave, Helena, MT 59601-0552 Ph: (406) 443-3331 | Dr Meghan E Cavazos, PHARMD 3095 N Montana Ave, Helena, MT 59601-0552 Ph: (406) 443-3331 |
News Archive
One of the earliest known impairments caused by Alzheimer's disease - loss of sense of smell - can be restored by removing a plaque-forming protein in a mouse model of the disease, a study led by a Case Western Reserve University School of Medicine researcher finds.
New research has revealed that a synthetic form of cannabis is being consumed and has shown up in one in ten West Australian mine workers' urine samples. The state's ChemCentre provides forensic testing for police and the State Coroner. They have been given the contract on an increasing basis by private companies in mining regions to test their workers for the substance, known as Kronic.
Patients with the skin disease psoriasis appear more likely to have higher levels of leptin (a hormone produced by fat cells that may contribute to obesity and other metabolic abnormalities) than persons without psoriasis, according to a report in the December issue of Archives of Dermatology.
Roche (SIX: ROG.VX; RO.S, OTCQX: RHHBY) and InterMune, Inc. (Nasdaq: ITMN) today announced that the first patient has been dosed in a Phase 2b study evaluating the hepatitis C virus (HCV) protease inhibitor, RG7227/ ITMN-191, in combination with PEGASYS(R) (pegylated interferon alfa-2a) and COPEGUS(R) (ribavirin). The study, to be conducted at 45 sites globally, will further define the safety and efficacy profile of RG7227/ ITMN-191, for a treatment duration of up to 24 weeks. Approximately 300 treatment-naive patients chronically infected with HCV genotype 1 - the most difficult to treat form of the virus - will participate.
› Verified 3 days ago
Stephanie Kate Wuerffel, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1531 Flowerree St, Helena, MT 59601 Phone: 406-209-6006 | |
Taylor Shea Hopson, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2550 E Broadway St, Helena, MT 59601 Phone: 406-444-2350 | |
Cortnie Reign Peters, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2475 E Broadway St, Helena, MT 59601 Phone: 406-442-2480 | |
Ceder Dorrington-thacker, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2475 E Broadway St, Helena, MT 59601 Phone: 406-781-3670 | |
Brett Amestoy, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2475 E Broadway St, Helena, MT 59601 Phone: 406-444-2350 | |
Pamela I Melton, PHARM D Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2475 E Broadway St, Helena, MT 59601 Phone: 406-495-6967 |